CompletedNot Applicable

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

Côte d’Ivoire767,535 participantsStarted 2021-08-27

Plain-language summary

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.

Who can participate

Age range1 Month – 11 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ages 1 to 11 months * Resident in targeted community Exclusion Criteria: * Children below 3.0 kg (3rd centile for healthy 1-month old infants in the WHO growth charts) * Appears seriously ill at the time of the MDA (per the CDD's assessment) * Unable to swallow liquid delivered through a needle-less syringe because of physical limitations * Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide * prior allergic reaction to medication likely to be a macrolide

What they're measuring

% of eligible population covered by intervention

Timeframe: three years

Infant mortality rate

Timeframe: three years

Implementation fidelity

Timeframe: three years

Trial details

NCT IDNCT05016895

SponsorFHI 360

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Child Mortality trials